PPT-Update in Hodgkins & DLBCL

Andy Chen MD PhD Center for Hematologic Malignancies Knight Cancer Institute Oregon Health amp Science University January 2012 Disclosures Clinical trials Seattle Genetics Otsuka Genentech. NATUROPATHIC MEDICINE. 84 YEAR YOUNG FEMALE WITH HODGKINS LYMPHOMA. Barbara presented to my clinic in June of 2007, with a diagnosis of Hodgkin's Lymphoma. She had been previously diagnosed by oncologist in 2003.. Koç University Medical School Istanbul/Turkey. Aegean Hematology Oncology Symposium 17-20 Sep 2015. Is . R-CHOP . the standart treatment . for . high-risk DLBCL. Objectives. Introduction and risk assesment of DLBCL. Program Goals. DLBCL Subtypes . 2008 WHO Classification. Other DLBCL Variants. Dissecting DLBCL into Molecularly and Clinically Distinct Subgroups by Gene Expression Profiling. Outcomes Based on DLBCL Subtype Using Gene Expression Profiling. November 10, 2021. Course Director. John P. Leonard, MD. Senior Associate Dean for Innovation and Initiatives. Executive Vice Chair, Weill Department of Medicine. Richard T. Silver Distinguished Professor of Hematology & Medical Oncology. B-Cell . Lymphoma (DLBCL) Patients, . 1983 . – 2014. results from . analysis of US SEER data. Ron . Dewar, . Registry and . Analytics,. Nova Scotia Health Authority (Canada). Nadia . Howlader. , Angela . Dr. Gilles SALLES. Chief . of. . the. . Lymphoma. Service. Memorial Sloan Kettering Cancer Center, New York. New agents in DLBCL. Recently FDA approved agents:. Polatuzumab. . vedotin. Selinexor. MODERATOR : DR. GANAPULE . Definition . Lymphomas are malignant . tumours. of lymphoid tissue which give rise to solid tissue masses.. Heterogenous. group of disorders.. HODGKINS LYMPHOMA. NON-HODGKINS. contributes inferior outcome in DLBCL . . R4 . 簡聖軒. 指導老師. : . 高志平大夫. Outline . Maturation of B lymphocyte . DLBCL classification . Souto GR, Pereira TSF, Castro AF, Mesquita RA. Diffuse large B-cell eMail: jced@jced.es Scopus DOI® System oi:10.4317/jced.51127http://dx.doi.org/10.4317/jced.51127IntroductionDiffuse large B-cell Dr. Sanne Lugthart. (. Dr. Stephen Robinson). University Hospital Bristol. 20 June 2019. Scope Of Talk. Current CAR T products available for NHS patients. The CAR T pathway (up to re-infusion). Patients Cases. (PMAL) Consortium and Associated Trials. 2016. CONFIDENTIAL. The new name for . Leukaemia. & Lymphoma Research. Tackling Diffuse Large B-cell Lymphoma. 2. Clinical Problem. Standard of care, RCHOP, results in cure rates around 75%. the single institute experience in Taiwan . Sheng. . Hsuan,Chien. , MD . Division of Hematology and Oncology,. Department of medicine, Taipei Veteran General Hospital. National Yang-Ming University School of medicine, Taipei, Taiwan . Diffuse Large B Cell Lymphoma. Foroud. . shahbazi. . Pharm.D. Introduction . Diffuse large B cell lymphoma (DLBCL) is the most common form . of aggressive . NHL accounting for approximately 30%-40% of cases. Prof. Georg Lenz, MD. Department of Haematology, Oncology and Pneumology. University Hospital Münster, Germany. May 2020 . 2. 3. LYMPHOMA CONNECT. is supported by an Independent Educational Grant from Bayer.